Wide Ranks

CRDF

Cardiff Oncology, Inc.

2.54

Top Statistics
Market Cap 129 M Forward PE -2.37 Revenue Growth 17.00 %
Current Ratio 4.74 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.61 Enterprise / Revenue 107.41 Price To Sales Trailing12 Months 188.78
Profitability
Profit Margins 0.00 % Operating Margins -7636.97 %
Balance Sheet
Total Cash 57 M Total Cash Per Share 1.13 Total Debt 1 M
Total Debt To Equity 3.41 Current Ratio 4.74 Book Value Per Share 1.01
All Measures
Short Ratio 720.00 % Message Board Id finmb_10959548 Shares Short Prior Month 7 M
Return On Equity -0.6757 City San Diego Uuid 66310195-132e-37e2-aefd-b05ac5a2eb8a
Previous Close 2.46 First Trade Date Epoch Utc 1 B Book Value 1.01
Beta 1.93 Total Debt 1 M Volume 640535
Price To Book 2.50 Last Split Date 1 B Fifty Two Week Low 1.21
Total Cash Per Share 1.13 Total Revenue 688000 Shares Short Previous Month Date 1 B
Target Median Price 8.31 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -7636.97 % Target Mean Price 9.16 Net Income To Common -43005000
Short Percent Of Float 0.1547 Implied Shares Outstanding 51 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 620560 Average Volume10days 620560
Total Cash 57 M Next Fiscal Year End 1 B Revenue Per Share 0.0150
Held Percent Insiders 0.0660 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.46 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.83 Open 2.47
Free Cashflow -19853876 State CA Dividend Yield 0.00 %
Return On Assets -0.3833 Time Zone Short Name EST Trailing Eps -0.9500
Day Low 2.44 Address1 11055 Flintkote Avenue Shares Outstanding 51 M
Price Hint 4 Target High Price 13.00 Website https://www.cardiffoncology.com
52 Week Change 1.07 Average Volume 720134 Forward Eps -1.01
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 465.30 %
Last Split Factor 1:6 Regular Market Day High 2.54 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 3.41 Fifty Two Week High 6.42
Day High 2.54 Shares Short 7 M Regular Market Open 2.47
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 107.41
Revenue Growth 17.00 % Shares Percent Shares Out 0.1509 Operating Cashflow -34565000
Currency USD Time Zone Full Name America/New_York Market Cap 129 M
Is_nasdaq_100 False Zip 92121 Quote Type EQUITY
Industry Biotechnology Long Name Cardiff Oncology, Inc. Regular Market Day Low 2.44
Held Percent Institutions 0.2598 Current Price 2.54 Enterprise To Ebitda -1.61
Financial Currency USD Current Ratio 4.74 Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country United States Float Shares 47 M
Two Hundred Day Average 3.11 Enterprise Value 73 M Price To Sales Trailing12 Months 188.78
Forward PE -2.37 Regular Market Volume 640535 Ebitda -46000000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.

Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

The company primarily serves pharmaceutical manufacturers.

The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.

Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.